
34: Weekly Dose Podcast: New AD Blood Test, Elinzanetant’s Sleep Effects, Lung Cancer Screening Success, Menopause Symptom Burden, and VMS Treatment Approval
0:00
4:17
This week on the Weekly Dose Podcast from Patient Care Online®, we break down five major clinical updates shaping primary care practice—from advances in Alzheimer diagnostics to new treatment options for menopause-related symptoms.
In this episode:
• First blood test for Alzheimer disease cleared for primary care
The Elecsys pTau181 assay offers a minimally invasive way to help rule out AD-related amyloid pathology, with a 97.9% negative predictive value in early-disease, low-prevalence settings.
• How elinzanetant improves sleep—independent of vasomotor symptom relief
A pooled analysis of more than 1,300 participants shows that over half of the therapy’s sleep benefit reflects direct effects on sleep pathways.
• Multidisciplinary lung cancer screening program delivers major gains
Screening rates more than doubled, disparities narrowed, and most cancers diagnosed were early stage—highlighting the power of coordinated population health infrastructure.
• Nationwide survey reveals the full scope of menopause symptoms
Fatigue, sleep disturbance, stress, brain fog, and weight gain were more prevalent than classic hot flushes, underscoring the need for holistic menopause care.
• FDA approves elinzanetant for moderate-to-severe vasomotor symptoms
The first dual NK-1/NK-3 receptor antagonist demonstrated rapid and sustained VMS reductions, plus improvements in sleep and quality of life.
Listen for fast, evidence-based insights to support your daily primary care practice.
For more clinical news and expert commentary, visit PatientCareOnline.com.
In this episode:
• First blood test for Alzheimer disease cleared for primary care
The Elecsys pTau181 assay offers a minimally invasive way to help rule out AD-related amyloid pathology, with a 97.9% negative predictive value in early-disease, low-prevalence settings.
• How elinzanetant improves sleep—independent of vasomotor symptom relief
A pooled analysis of more than 1,300 participants shows that over half of the therapy’s sleep benefit reflects direct effects on sleep pathways.
• Multidisciplinary lung cancer screening program delivers major gains
Screening rates more than doubled, disparities narrowed, and most cancers diagnosed were early stage—highlighting the power of coordinated population health infrastructure.
• Nationwide survey reveals the full scope of menopause symptoms
Fatigue, sleep disturbance, stress, brain fog, and weight gain were more prevalent than classic hot flushes, underscoring the need for holistic menopause care.
• FDA approves elinzanetant for moderate-to-severe vasomotor symptoms
The first dual NK-1/NK-3 receptor antagonist demonstrated rapid and sustained VMS reductions, plus improvements in sleep and quality of life.
Listen for fast, evidence-based insights to support your daily primary care practice.
For more clinical news and expert commentary, visit PatientCareOnline.com.
Mais episódios de "Primary Viewpoints: A Patient Care Podcast"



Não percas um episódio de “Primary Viewpoints: A Patient Care Podcast” e subscrevê-lo na aplicação GetPodcast.







